Premium
Response to high‐dose ifosfamide in patients with advanced/recurrent Ewing sarcoma
Author(s) -
Ferrari S.,
del Prever A. Brach,
Palmerini E.,
Staals E.,
Berta M.,
Balladelli A.,
Picci P.,
Fagioli F.,
Bacci G.,
Vanel D.
Publication year - 2009
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.21917
Subject(s) - ifosfamide , medicine , neutropenia , sarcoma , chemotherapy , progressive disease , blood cancer , mesna , toxicity , oncology , response evaluation criteria in solid tumors , surgery , cancer , pathology , cisplatin
Aim To determine activity and toxicity of high‐dose ifosfamide (HDIFO) in recurrent or advanced Ewing sarcoma family tumors (EFT). Methods Thirty‐seven EFT patients [median age 17 years (6–45 years)] previously treated with chemotherapy regimens including standard dose ifosfamide were enrolled. HDIFO was administered for metastatic recurrent disease in 33 patients and for progression during neoadjuvant chemotherapy in 4 patients. All patients who received two courses of 15 g/m 2 ifosfamide were evaluable for radiographic response assessed according to RECIST criteria. Results Transient Grade 4 neutropenia and thrombocytopenia in 97% and 54% HDIFO courses respectively and severe CNS toxicity in one patient were observed. Thirty‐five patients were evaluable: 12 (34%) had complete (2) or partial (10) response, 11 (32%) had stable disease, and 12 (34%) had progression. Conclusions In patients with relapsed or advanced EFT previously treated with standard dose ifosfamide HDIFO is active and it should be considered a treatment option. Pediatr Blood Cancer 2009;52:581–584. © 2009 Wiley‐Liss, Inc.